Penserra Capital Management LLC Purchases Shares of 4,669 DaVita Inc. (NYSE:DVA)

Penserra Capital Management LLC bought a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,669 shares of the company's stock, valued at approximately $765,000.

Several other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its position in DaVita by 0.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,286 shares of the company's stock worth $11,775,000 after purchasing an additional 533 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its stake in shares of DaVita by 9.9% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 2,308 shares of the company's stock valued at $319,000 after acquiring an additional 207 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of DaVita by 0.3% in the 1st quarter. California State Teachers Retirement System now owns 87,458 shares of the company's stock valued at $12,074,000 after acquiring an additional 241 shares during the last quarter. Comerica Bank boosted its holdings in shares of DaVita by 41.4% during the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock valued at $4,753,000 after acquiring an additional 10,074 shares in the last quarter. Finally, Plato Investment Management Ltd bought a new stake in DaVita during the 1st quarter worth $377,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DVA shares. Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. Barclays lifted their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Finally, Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus target price of $161.80.

DaVita Trading Down 1.3 %

NYSE:DVA opened at $165.71 on Thursday. DaVita Inc. has a 52 week low of $98.26 and a 52 week high of $169.51. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The firm's fifty day moving average is $158.42 and its 200-day moving average is $148.87. The firm has a market cap of $13.59 billion, a P/E ratio of 17.88, a P/E/G ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the company posted $2.85 EPS. The business's revenue was up 4.6% compared to the same quarter last year. Equities analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the firm's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the sale, the chief executive officer now directly owns 887,835 shares in the company, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.